Clinical Practice

Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

Emerging immunotherapy combination strategies in genitourinary malignancies

Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer   

Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences   

Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment   

Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient